Taro Pharmaceutical Industries Ltd.

Taro Pharmaceutical Industries Ltd. (NYSE: TARO), relating to its proposed sale to Sun Pharmaceutical Industries Ltd. Under the terms of the agreement, TARO shareholders are expected to receive $43.00 in cash per share they own.

M.D.C. Holdings, Inc.

M.D.C. Holdings, Inc. (NYSE: MDC), relating to its proposed sale to Sekisui House, Ltd. Under the terms of the agreement, MDC shareholders are expected to receive $63.00 in cash per share they own.

Kaman Corp.

Kaman Corp. (NYSE: KAMN), relating to its proposed sale to Arcline Investment Management, L.P. Under the terms of the agreement, KAMN shareholders are expected to receive $46.00 in cash per share they own.

Tricon Residential, Inc.

Tricon Residential, Inc. (NYSE: TCN), relating to its proposed sale to Blackstone. Under the terms of the agreement, TCN shareholders are expected to receive $11.25 in cash per share they own.

Southwestern Energy Co.

Southwestern Energy Co. (NYSE: SWN), relating to its proposed sale to Chesapeake Energy Corp. Under the terms of the agreement, SWN shareholders are expected to receive between 0.0867 shares of Chesapeake common stock per share they own.

Electrameccanica Vehicles Corp.

Electrameccanica Vehicles Corp. (Nasdaq: SOLO), relating to its proposed merger with Xos, Inc. Under the terms of the agreement, SOLO shareholders are expected to own approximately 21% of the combined company.

Theseus Pharmaceuticals, Inc.

Theseus Pharmaceuticals, Inc. (Nasdaq: THRX), relating to its proposed sale to Concentra Biosciences, LLC. Under the terms of the agreement, THRX shareholders are expected to receive between $3.90 and $4.05 in cash per share they own

Via Renewables, Inc.

Via Renewables, Inc. (Nasdaq: VIA), relating to its proposed sale to Retailco, LLC. Under the terms of the agreement, VIA shareholders will receive $11.00 in cash per share they own.

Ambrx Biopharma, Inc.

Ambrx Biopharma, Inc. (Nasdaq: AMAM), relating to its proposed sale to Johnson & Johnson. Under the terms of the agreement, AMAM shareholders will receive $28.00 in cash per share they own.

Harpoon Therapeutics, Inc.

Harpoon Therapeutics, Inc. (Nasdaq: HARP), relating to its proposed sale to Merck. Under the terms of the agreement, HARP shareholders will receive $23.00 in cash per share they own.